An investment theme focused on strengthening CRO and PMS capabilities through the acquisition of ArkMS株式会社, expanding capabilities in clinical development, regulatory submissions and post-marketing surveillance (PMS). The initiative will capitalize on relationships with medical institutions and pharmaceutical companies to expand an integrated support platform for pharmaceutical development.